SCHEMBL3490936

SCHEMBL3490936

O=C1N(Cc2ccccc2)c2cc(Cl)cc(N3CCNCC3)c2S(=O)(=O)N1Cc1cccc(O)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 6/20 0.42
SLC6A2 P23975 2/20 0.40
SLC6A4 P31645 2/20 0.40
SLC6A3 Q01959 2/20 0.40
MAPT P10636 3/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
KMT2A Q03164 1/20 0.39
ME1 P48163 1/20 0.38
DRD2 P14416 2/20 0.36
DRD3 P35462 2/20 0.36
ADRB2 P07550 1/20 0.36
HTR1D P28221 1/20 0.36
HTR1B P28222 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
ADRA1B P35368 1/20 0.36
HTR2B P41595 1/20 0.36
MRGPRX1 Q96LB2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3489858 0.92 HTR6 (0.45) HTR6SLC6A2SLC6A4SLC6A3MAPT
SCHEMBL13500378 0.90 MAPT (0.42) MAPTMEN1ALDH1A1LMNAKMT2A
SCHEMBL3491519 0.89 EGFR (0.42) HTR6MAPTMEN1KMT2ADRD2
SCHEMBL3489941 0.87 HTR6 (0.41) HTR6SLC6A2SLC6A4SLC6A3MAPT
SCHEMBL3490336 0.86 CMA1 (0.44) HTR6SLC6A2SLC6A4MEN1ALDH1A1
SCHEMBL3489119 0.85 HTR6 (0.43) HTR6MAPTDRD2DRD3HTR2A
SCHEMBL3489084 0.85 MAPT (0.47) HTR6SLC6A2SLC6A4MAPTHTR2C
SCHEMBL3488616 0.85 HTR6 (0.41) HTR6SLC6A2SLC6A4SLC6A3MAPT
SCHEMBL3490431 0.84 HTR3A (0.42) HTR6MAPTMEN1ALDH1A1LMNA
SCHEMBL3488986 0.84 HTR6 (0.41) HTR6MAPTDRD2DRD3HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME OPRD1, HTR6, HTR1D HTR6 2/4885SLC6A2 205/4885SLC6A4 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.